4CPS-031 Efficacy and safety of high-dose twice-weekly sebelipase alfa in severe-onset Wolman disease: a case report

A Castro Balado; MJ de Castro López; P Sánchez Pintos; EJ Bandín Vilar; JM Giráldez Montero; L García Quintanilla; ML Couce Pico; I Zarra Ferro

doi:10.1136/ejhpharm-2022-eahp.78

Article info

PDF

Section 4: Clinical pharmacy services

4CPS-031 Efficacy and safety of high-dose twice-weekly sebelipase alfa in severe-onset Wolman disease: a case report

Free

Authors

A Castro Balado Complejo Hospitalario Universitario de Santiago de Compostela, Hospital Pharmacist Service, Santiago de Compostela, Spain PubMed articles Google scholar articles
MJ de Castro López Complejo Hospitalario Universitario de Santiago de Compostela, Paediatric Inherited Metabolic Diseases, Santiago de Compostela, Spain PubMed articles Google scholar articles
P Sánchez Pintos Complejo Hospitalario Universitario de Santiago de Compostela, Paediatric Inherited Metabolic Diseases, Santiago de Compostela, Spain PubMed articles Google scholar articles
EJ Bandín Vilar Complejo Hospitalario Universitario de Santiago de Compostela, Hospital Pharmacist Service, Santiago de Compostela, Spain PubMed articles Google scholar articles
JM Giráldez Montero Complejo Hospitalario Universitario de Santiago de Compostela, Hospital Pharmacist Service, Santiago de Compostela, Spain PubMed articles Google scholar articles
L García Quintanilla Complejo Hospitalario Universitario de Santiago de Compostela, Hospital Pharmacist Service, Santiago de Compostela, Spain PubMed articles Google scholar articles
ML Couce Pico Complejo Hospitalario Universitario de Santiago de Compostela, Paediatric Inherited Metabolic Diseases, Santiago de Compostela, Spain PubMed articles Google scholar articles
I Zarra Ferro Complejo Hospitalario Universitario de Santiago de Compostela, Hospital Pharmacist Service, Santiago de Compostela, Spain PubMed articles Google scholar articles

Citation

Castro Balado A, de Castro López M, Sánchez Pintos P, et al

4CPS-031 Efficacy and safety of high-dose twice-weekly sebelipase alfa in severe-onset Wolman disease: a case report

European Journal of Hospital Pharmacy 2022;29:A37.

Publication history

First published March 23, 2022.

Online issue publication

April 22, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password